ARTICLE | Clinical News
Palonosetron: Began Phase III testing
April 10, 2000 7:00 AM UTC
Helsinn Healthcare SA, Lugano, Switzerland Product: Palonosetron Business: Cancer Therapeutic category: Receptor antagonist, Adjunct Target: 5-HT3 receptor Description: Selective 5-HT3 receptor antago...